Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study (Q42504591)

1 November 2017

Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study (English)

1 reference

1 November 2017

0 references

Lazar L

1

1 reference

1 November 2017

Ofan R

2

1 reference

1 November 2017

Weintrob N

3

1 reference

1 November 2017

Avron A

4

1 reference

1 November 2017

Tamir M

5

1 reference

1 November 2017

Elias D

6

1 reference

1 November 2017

Phillip M

7

1 reference

1 November 2017

Josefsberg Z

8

1 reference

1 November 2017

1 May 2007

1 reference

Diabetes - Metabolism: Research and Reviews

1 November 2017

1 reference

1 November 2017

23

1 reference

1 November 2017

286-291

1 reference

1 November 2017

4

1 reference

Type I diabetes mellitus. A chronic autoimmune disease

1 November 2017

1 reference

7 January 2021

Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis

1 reference

7 January 2021

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

1 reference

7 January 2021

Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus

1 reference

7 January 2021

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

1 reference

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

7 January 2021

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

1 reference

7 January 2021

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

1 reference

7 January 2021

Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin

1 reference

7 January 2021

Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks

1 reference

7 January 2021

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

7 January 2021

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

7 January 2021

Breeding of a non-obese, diabetic strain of mice

1 reference

7 January 2021

Peptide therapy for diabetes in NOD mice

1 reference

7 January 2021

Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens

1 reference

7 January 2021

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

1 reference

7 January 2021

A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM

1 reference

7 January 2021

Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve

1 reference

7 January 2021

Age-dependent influences on the origins of autoimmune diabetes: evidence and implications

1 reference

7 January 2021

T cells and autoantibodies to human HSP70 in type 1 diabetes in children

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.711

1 reference

1 November 2017

1 reference